Skip to Content

Notice

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Investigational New Drug Regulations

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble Start Printed Page 8590

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES:

Fax written comments on the collection of information by March 20, 2006.

ADDRESSES:

OMB is still experiencing significant delays in the regular mail, including first class and express mail, and messenger deliveries are not being accepted. To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: Fumie Yokota, Desk Officer for FDA, FAX: 202-395-6974.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Karen Nelson, Office of Management Programs (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1482.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

Investigational New Drug Regulations—(OMB Control Number 0910-0014)—Extension

FDA is requesting OMB approval for the reporting and recordkeeping requirements contained in the FDA regulation “Investigational New Drug Application” in part 312 (21 CFR part 312). This regulation implements provisions of section 505(i) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(i)) to issue regulations under which the clinical investigation of the safety and effectiveness of unapproved new drugs and biological products can be conducted.

FDA is charged with implementing statutory requirements that drug products marketed in the United States be shown to be safe and effective, properly manufactured, and properly labeled for their intended uses. Section 505(a) of the act provides that a new drug may not be introduced or delivered for introduction into interstate commerce in the United States unless FDA has previously approved a new drug application (NDA). FDA approves an NDA only if the sponsor of the application first demonstrates that the drug is safe and effective for the conditions prescribed, recommended, or suggested in the product's labeling. Proof must consist, in part, of adequate and well-controlled studies, including studies in humans, that are conducted by qualified experts. The IND regulations establish reporting requirements that include an initial application as well as amendments to that application, reports on significant revisions of clinical investigation plans, and information on a drug's safety or effectiveness. In addition, the sponsor is required to give FDA an annual summary of the previous year's clinical experience. Submissions are reviewed by medical officers and other agency scientific reviewers assigned responsibility for overseeing the specific study. The IND regulations also contain recordkeeping requirements that pertain to the responsibilities of sponsors and investigators. The detail and complexity of these requirements are dictated by the scientific procedures and human subject safeguards that must be followed in the clinical tests of investigational new drugs.

The IND information collection requirements provide the means by which FDA can do the following: (1) Monitor the safety of ongoing clinical investigations; (2) determine whether the clinical testing of a drug should be authorized; (3) ensure production of reliable data on the metabolism and pharmacological action of the drug in humans; (4) obtain timely information on adverse reactions to the drug; (5) obtain information on side effects associated with increasing doses; (6) obtain information on the drug's effectiveness; (7) ensure the design of well-controlled, scientifically valid studies; (8) obtain other information pertinent to determining whether clinical testing should be continued and information related to the protection of human subjects. Without the information provided by industry in response to the IND regulations, FDA cannot authorize or monitor the clinical investigations which must be conducted prior to authorizing the sale and general use of new drugs. These reports enable FDA to monitor a study's progress, to assure subject safety, to assure that a study will be conducted ethically, and to increase the likelihood that the sponsor will conduct studies that will be useful in determining whether the drug should be marketed and available for use in medical practice.

There are two forms that are required under part 312. The first is Form FDA-1571 “Investigational New Drug Application.” A person who intends to conduct a clinical investigation submits this form to FDA. It includes the following information: (1) A cover sheet containing background information on the sponsor and investigator, (2) a table of contents, (3) an introductory statement and general investigational plan, (4) an investigator's brochure describing the drug substance, (5) a protocol for each planned study, (6) chemistry, manufacturing, and control information for each investigation, (7) pharmacology and toxicology information for each investigation, and (8) previous human experience with the investigational drug.

The second form required under part 312 is Form FDA-1572 “Investigator Statement.” Before permitting an investigator to begin participation in an investigation, the sponsor must obtain and record this form. It includes background information on the investigator and the investigation, and a general outline of the planned investigation and the study protocol.

In the Federal Register of October 12, 2005 (70 FR 59350), FDA published a 60-day notice requesting public comments on the information collection provisions. No comments were received that pertained to the information collection burden estimates.

FDA is requesting OMB approval for the following reporting and recordkeeping requirements in part 312:

Table 1.

REPORTING REQUIREMENTS
21 CFR SectionRequirements
312.7(d)Applications for permission to sell an investigational new drug.
Start Printed Page 8591
312.10(a)Applications for waiver of requirements under part 312. Estimates for this requirement are included under §§ 312.23 and 312.31.
312.20(c)Applications for investigations involving an exception from informed consent under § 50.24 (21 CFR 50.24). Estimates for this requirement are included under § 312.23.
312.23INDs (content and format).
(a)(1)Cover sheet FDA-1571.
(a)(2)Table of contents.
(a)(3)Investigational plan for each planned study.
(a)(5)Investigator's brochure.
(a)(6)Protocols—phases 1, 2, and 3.
(a)(7)Chemistry, manufacturing, and control information.
(a)(7)(iv)(a), (a)(7)(iv)(b), and (a)(7)(iv)(c)A description of the drug substance, a list of all components, and any placebo used.
(a)(7)(iv)(d)Labeling: Copies of labels and labeling to be provided each investigator.
(a)(7)(iv)(e)Environmental impact analysis regarding drug manufacturing and use.
(a)(8)Pharmacological and toxicology information.
(a)(9)Previous human experience with the investigational drug.
(a)(10)Additional information.
(a)(11)Relevant information.
(f)Identification of exception from informed consent.
312.30Protocol amendments.
(a)New protocol.
(b)Change in protocol.
(c)New investigator.
(d)Content and format.
(e)Frequency.
312.31Information amendments.
(b)Content and format. Chemistry, toxicology, or technical information.
312.32Safety reports.
(c)(1)Written reports to FDA and to investigators.
(c)(2)Telephone reports to FDA for fatal or life-threatening experience.
(c)(3)Format or frequency.
(d)Followup submissions.
312.33Annual reports.
(a)Individual study information.
(b)Summary information.
(b)(1)Adverse experiences.
(b)(2)Safety report summary.
(b)(3)List of fatalities and causes of death.
(b)(4)List of discontinuing subjects.
(b)(5)Drug action.
(b)(6)Preclinical studies and findings.
(b)(7)Significant changes.
(c)Next year general investigational plan.
(d)Brochure revision.
(e)Phase I protocol modifications.
(f)Foreign marketing developments.
312.35Treatment use of investigational new drugs.
(a)Treatment protocol submitted by an investigational new drug sponsor.
(b)Treatment investigational new drug application (IND) submitted by licensed practitioner.
312.36Requests for emergency use of an investigational new drug.
312.38(b) and (c)Notification of withdrawal of an investigational new drug.
312.42(e)Sponsor requests that a clinical hold be removed and submits a complete response to the issues identified in the clinical hold order.
312.44(c) and (d)Opportunity for sponsor response to FDA when an investigational new drug is terminated.
312.45(a) and (b)Sponsor request for, or response to, inactive status determination of an investigational new drug.
312.47(b)“End-of-Phase 2” meetings and “Pre-NDA” meetings.
312.53(c)Investigator information. Investigator report (Form FDA-1572) and narrative; Investigator's background information; phase 1 outline of planned investigation; and phase 2 outline of study protocol; financial disclosure information.
312.54(a) and (b)Sponsor submissions concerning investigations involving an exception from informed consent under § 50.24.
Start Printed Page 8592
312.55(b)Sponsor reports to investigators on new observations, especially adverse reactions and safe use. Only “new observations” are estimated under this section; investigator brochures are included under § 312.23.
312.56(b), (c), and (d)Sponsor monitoring of all clinical investigations, investigators, and drug safety; notification to FDA.
312.58(a)Sponsor's submission of records to FDA on request.
312.64Investigator reports to the sponsor.
(a)Progress reports.
(b)Safety reports
(c)Final reports.
(d)Financial disclosure reports.
312.66Investigator reports to Institutional Review Board. Estimates for this requirement are included under § 312.53.
312.70(a)Investigator disqualification; opportunity to respond to FDA.
312.83Sponsor submission of treatment protocol. Estimates for this requirement are included under §§ 312.34 and 312.35.
312.85Sponsors conducting phase 4 studies. Estimates for this requirement are included under § 312.23 in OMB control number 0910-0014, and §§ 314.50, 314.70, and 314.81 (21 CFR 314.50, 314.70, and 314.81) in OMB control number 0910-0001.
312.110(b)Request to export an investigational drug.
312.120(b) and (c)(2)Sponsor's submission to FDA for use of foreign clinical study to support an IND. Estimates for this requirement are included under §§ 312.23 and 312.30 in OMB control number 0910-0014, and §§ 314.50, 314.60, and 314.70 (21 CFR 314.60) in OMB control number 0910-0001.
312.120(c)(3)Sponsor's report to FDA on findings of independent review committee on foreign clinical study. Estimates for this requirement are included under §§ 312.23 and 312.30 in OMB control number 0910-0014, and §§ 314.50, 314.60, and 314.70 in OMB control number 0910-0001.
312.130(d)Request for disclosable information for investigations involving an exception from informed consent under § 50.24.
RECORDKEEPING REQUIREMENTS
21 CFR SectionRequirements
312.52(a)Transfer of obligations to a contract research organization.
312.57(a) and (b)Sponsor recordkeeping.
312.59Sponsor recordkeeping of disposition of unused supply of drugs. Estimates for this requirement are included under § 312.57.
312.62(a)Investigator recordkeeping of disposition of drugs.
312.62(b)Investigator recordkeeping of case histories of individuals.
312.160(a)(3)Records maintenance: shipment of drugs for investigational use in laboratory research animals or in vitro tests.
312.160(c)Shipper records of alternative disposition of unused drugs.

In tables 2 and 3 of this document, the estimates for “No. of Respondents,” “No. of Responses per Respondent,” and “Total Annual Responses” were obtained from the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) reports and data management systems for submissions received in 2004 and from other sources familiar with the number of submissions received under part 312. The estimates for “Hours per Response” were made by CDER and CBER individuals familiar with the burden associated with these reports and from estimates received from the pharmaceutical industry.

FDA estimates the burden of this collection of information as follows:

Table 2.—Estimated Annual Reporting and Recordkeeping Burden for Human Drugs1

REPORTING BURDEN
21 CFR SectionNo. of RespondentsNo. of Responses per RespondentTotal Annual ResponsesHours per ResponseTotal Hours
312.7(d)91.413247,488
312.23(a) through (f)1,2451.31,5971,6002,555,200
Start Printed Page 8593
312.30(a) through (e)1,25713.316,6872844,739,108
312.31(b)1,1167.48,298100829,800
312.32(c) and (d)64924.716,05232513,664
312.33(a) through (f)1,8212.54,5163601,625,760
312.35(a) and (b)51.263001,800
312.361091.1121161,936
312.38(b) and (c)5361.36772818,965
312.42(e)971.211828433,512
312.44(c) and (d)4414516720
312.45(a) and (b)1851.5271123,252
312.47(b)2151.735516056,800
312.53(c)21,194121,194801,695,520
312.54(a) and (b)000480
312.55(b)807,4001807,4004838,755,200
312.56(b), (c), and (d)13113801,040
312.58(a)883.834082,720
312.64(a) through (d)31,791131,79124762,984
312.70(a)41440160
312.110(b)338.32767520,700
312.130(d)515840
Total reporting burden51,626,369
RECORDKEEPING BURDEN
21 CFR SectionNo. of RecordkeepersNo. of Records per RecordkeeperTotal Annual RecordsHours per RecordTotal Hours
312.52(a)3351.54882976
312.57(a) and (b)335119.840,1481004,014,800
312.62(a)20,074120,07440802,960
312.62(b)200,7401200,740408,029,600
312.160(a)(3)3721.5542.5271
312.160(c)3721.5542.5271
Total recordkeeping burden12,848,878
Human drugs total burden hours64,475,247
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
Start Printed Page 8594

Table 3.—Estimated Annual Reporting and Recordkeeping Burden for Biologics1

REPORTING BURDEN
21 CFR SectionNo. of RespondentsNo. of Responses per RespondentTotal Annual ResponsesHours per ResponseTotal Hours
312.7(d)411.458241,392
312.23(a) through (f) and 312.120(b), (c)(2), and (c)(3)4331.35571,8081,007,056
312.30(a) through (e)5906.84,0142841,139,976
312.31(b)26329.37,700100770,000
312.32(c) and (d) and 312.56(c)29413.74,04232129,344
312.33(a) through (f) and 312.56(c)6472.31,473360530,280
312.35(a) and (b)111300300
312.366161696
312.38(b) and (c)1171.3153284,284
312.42(e)741.510828430,672
312.44(c) and (d)171.11816288
312.45(a) and (b)601.8107121,284
312.47(b)431.56616010,560
312.53(c)3486.62,30380184,240
312.54(a) and (b)1114848
312.55(b)1382.53474816,656
312.56(b) and (d)141.623801,840
312.58(a)818864
312.64(a) through (d)6,0033.521,18524508,440
312.70(a)61640240
312.110(b)21121751,575
312.130(d)11188
Total reporting burden4,338,643
RECORDKEEPING BURDEN
21 CFR SectionNo. of RecordkeepersAnnual Frequency per RecordkeepingTotal Annual RecordsHours per RecordTotal Hours
312.52(a)1391.42002400
312.57(a) and (b)4332.61,114100111,400
312.62(a)5,57015,57040222,800
312.62(b)5,5701055,700402,228,000
312.160(a)(3)1461.42110.5105.5
312.160(c)1461.42110.5105.5
Total recordkeeping burden2,562,811
Total biologics burden hours6,901,454
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
Start Printed Page 8595

Table 4.—Estimated Annual Reporting and Recordkeeping Burden for Human Drugs and Biologics1

Total human drugs burden hours64,475,247
Total biologics burden hours6,901,454
Total burden hours71,376,701
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
Start Signature

Dated: February 9, 2006.

Jeffrey Shuren,

Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. E6-2289 Filed 2-16-06; 8:45 am]

BILLING CODE 4160-01-S